Akzo to Sell Biomaterials Technology to Ashland

In a transaction set to close in the third quarter of this year, AkzoNobel has announced plans to sell its biomaterials technology to Ashland of the US.

The Dutch chemical producer said the business is in its early phase of commercialization, and the divestment plans follow a strategic review that determined it was not a good fit with the company’s portfolio.

The activities are focused on plant-based chemistry used to develop products for various applications, such as high performance beauty technologies.

“This transaction will enable us to focus on our core technology platforms of specialty surfactants and polymers and help reinforce our leadership position in both areas,” Akzo Nobel said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read